Processa Pharmaceuticals Inc
$ 2.37
19.70%
11 Jun - close price
- Market Cap 6,517,900 USD
- Current Price $ 2.37
- High / Low $ 2.48 / 1.98
- Stock P/E N/A
- Book Value 0.95
- EPS -4.07
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.94 %
- ROE -4.65 %
- 52 Week High 14.25
- 52 Week Low 1.76
About
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of patients with unmet medical needs in the United States. The company is headquartered in Hanover, Maryland.
Analyst Target Price
$25.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-03-20 | 2024-10-30 | 2024-08-13 | 2024-05-10 | 2024-03-29 | 2023-11-13 | 2023-08-10 | 2023-05-15 | 2023-03-30 |
| Reported EPS | -0.07 | -0.25 | -0.3 | -0.74 | -1.03 | -1.01 | -1.11 | -1.7 | -0.08 | -0.097 | -0.18 | -0.36 |
| Estimated EPS | -0.45 | -0.23 | -1.18 | -0.92 | -1 | -0.98 | -1.18 | -1.6 | -0.1 | -0.23 | -0.28 | -0.32 |
| Surprise | 0.38 | -0.02 | 0.88 | 0.18 | -0.03 | -0.03 | 0.07 | -0.1 | 0.02 | 0.133 | 0.1 | -0.04 |
| Surprise Percentage | 84.4444% | -8.6957% | 74.5763% | 19.5652% | -3% | -3.0612% | 5.9322% | -6.25% | 20% | 57.8261% | 35.7143% | -12.5% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PCSA
2026-06-08 06:40:28
This article provides an analyst forecast for Processa Pharmaceuticals, Inc. (PCSA), detailing current consensus ratings, price targets, and forward estimates. It highlights a strong "Buy" consensus based on 5 analysts, with a 12-month average target significantly above the current stock price. The report also includes historical rating changes and a single recent price target.
2026-06-02 16:40:30
Wendy Guy, Chief Administrative Officer of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), purchased 1,829 shares of the company's common stock for $2.57 per share, totaling $4,700. This insider transaction occurred on May 29, 2026, bringing her direct holdings to 9,840 shares. The stock is currently trading near $2.53, having fallen 62% in the past six months, and InvestingPro analysis suggests it is undervalued with more cash than debt.
2026-06-02 04:40:05
Patrick Lin, Chief Business and Strategy Officer at Processa Pharmaceuticals, Inc. (PCSA), purchased 1,582 company shares for $2.57 each, totaling $4,065. This transaction comes as the stock trades near its 52-week low after a 62% decline in the past six months. InvestingPro analysis suggests the stock is undervalued, with the company maintaining more cash than debt.
2026-06-02 03:39:29
Processa Pharmaceuticals, Inc. CEO George K. Ng recently purchased 2,129 shares of the company's Common Stock at $2.57 per share in an open-market transaction on May 29, 2026. This purchase increased his direct holdings to 9,970 shares. The filing also revealed his indirect ownership of an additional 800 shares through the Ng Cha Family Trust and 3,488 shares through an IRRA account.
2026-06-01 20:39:29
Processa Pharmaceuticals' CFO, Russell Skibsted, purchased 2,292 shares of Common Stock at $2.57 per share in an open-market transaction on May 29, 2026. This acquisition increases his directly held position to 10,758 shares. The transaction, valued at approximately $5,890, signals confidence in the company's prospects.
2026-06-01 20:39:29
Wendy Guy, Chief Administrative Officer of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), recently purchased 1,829 shares of the company's common stock for $4,700. This insider acquisition occurred on May 29, 2026, with shares priced at $2.57 each. The stock is currently trading near $2.53, having fallen 62% in the last six months, and InvestingPro analysis suggests PCSA may be undervalued due to its cash position relative to debt.
